Rectally Administered Budesonide-Loaded Phase Transformable Premix Offers Improved Recovery of Intestinal Mucosa in Ulcerative Colitis
Abstract
bioadhesion experiments showed a prolonged residence of the LC formulation in the chicken ileum. The formulation was loaded with budesonide (BDS), and its efficacy was studied in a male C57BL/6 mouse model of ulcerative colitis (UC). Subsequent to rectal administration, therapeutic outcomes were compared in terms of biochemical and histopathological data. Western blotting was performed to evaluate the expression of colonic epithelial tight junction proteins (occludin and ZO-1). We found that the rectally administered formulation can alleviate the symptoms and pathological signatures of UC. The formulation exerted its effects by suppressing the oxidative stress-inflammation axis and restoring the integrity of the colonic barrier.
Fields of Study & Subjects
Barrier Structure and Function Studies
Inflammatory Bowel Disease
Advanced Drug Delivery Systems
Publication details
- Journal / source
- Langmuir
- Publisher
- American Chemical Society (ACS)
- Volume
- 42
- Issue
- 18
- Pages
- 12890–12900
- Publication date
- 1 May 2026
- Language
- EN